BioPharmX Corp fka BPMX

[Whos_Who]

Signs of the share price increase plan coming together for BioPharmX.

So far we've witnessed more of an internal shake-up for the better in the past few weeks, than we've seen from previous president Anja Krammer has done in the past year!

We've seen CEO Tierney cut overhead costs by firing Greg (CFO), Anja (President), and in my opinion, soon to be fired Morlock (who recently, unexpectedly, dumped all of his shares) most likely out of spite knowing the future demise of his position.

Tierney has found a new business location at around half the cost of the past facility, and with a quarterly burn rate of around 4.3M a quarter, it looks like Tierney wants to shave a good bit of costs off the next quarterly earnings report.

Tierney himself has purchased 100,000 shares of the business’s stock to show faith in the company.
Most importantly, Tierney's track record. Here is a CEO that recently led a team at Icon Bioscience, that in 2018 received U.S. FDA approval of its New Drug Application for DEXYCU. Dr. Tierney was president and chief operating officer of Oceana Therapeutics, a specialty therapeutic company he co-founded in 2008 and was later acquired by Salix Pharmaceuticals. In his role as president and chief executive officer of Valera Pharmaceuticals, Tierney raised over $65 million in funding and completed a successful IPO and oversaw NDA approvals of VANTAS and SUPPRELIN LA. In addition to Dr. Tierney’s leadership roles, he has extensive experience in raising capital and has held a position with investment firm, Signet Health Partners.

With a little research of the above mentioned companies, you will find that we now have a CEO with a stellar track record of mergers, acquisitions, and the ability to raise capital. Dr Tierney believes in BioPharmX and the product or he wouldn't have taken on the job. Failure is not an option in his resume!

Work is getting done behind the scenes and Institutional Investors approve!

Most recently a new 13D/A SEC filing in regards to Franklin Advisors and their shares increase of 3.5M since their last 13D/A filing in Dec. 2016 found here.
Here is the link to the most recent 13D/A filing here.

Past president Anja stated that they had many ioi's on the table to secure funding, although she failed to seal the deal. The big investors and original investors had Tierney brought in to save this "Holy Grail" investment that they know carries a superior product over the competition.

Between shake-ups at the higher level and the second largest institutional investor adding, you can't help but notice that positive things are finally getting done in favor for long term investors here! We have been brought down by a lazy, greedy, and incompetent past board of directors that is soon to be shown, has been corrected.

Mr Tierney has his hands full with cleaning up this mess, but as pointed out above, he is working! Remember, he was only brought on 7 weeks ago. I would expect nothing less than an amazing PR announcement to come soon! BioPharmX will be another example to Dr Tierney's stellar resume and track record of performance!